From the bench to the bedside: ways to improve rituximab efficacyGuillaume Cartron(Centre National de la Recherche Scientifique), Philippe Solal‐Céligny(Centre Jean Bernard)BloodJune 30, 200410.1182/blood-2004-03-1110Cited by 518SaveCiteExport RISWatch citationsRelated PapersClinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy|Cancers|2021|36